The Almirall Annual General Meeting approves 0.18* euro pay out per share as scrip dividend

• The pharmaceutical company distributes over 29 million euros as shareholder dividend payments  
• The scrip dividend will be paid out as cash or paid-up share 

• Almirall is expecting an intense schedule of news regarding Aclidinium and Linaclotide

Barcelona, 4^th May 2012.-  Almirall, the pharmaceutical company headquartered in Barcelona,  approved the distribution of €29.458.233 as dividend payments among its shareholders during its Annual General Meeting held today. A gross dividend of €0.18* per share will therefore be paid out in the form of scrip dividend on 1 June.

According to Jorge Gallardo, President of Almirall, “the flexible dividend proposal is for three reasons: to offer an attractive tax proposition to shareholders who wish to increase their shares in Almirall; to strengthen the balance sheet at a time when the company will be making significant commercial and R&D investments; and to give shareholders the chance to revalue the share price in the future, as we are awaiting an intense schedule of news about our key growth platforms: Aclidinium and Linaclotide”.

The agenda included approval of the annual accounts for 2011, in which Almirall obtained a Net Income of €84.2 MM. Meanwhile, the Normalised Net Income totalled €97.9 MM in line with forecasts to the market.

EBITDA for 2011 reached €160.1 MM. Net Sales stood at €768.4 MMand Other Income was €104.7 MM, with a resulting Total Income of €873.1 MM.

R&D Expenditure totalled €144.5 MM, led by progress of the respiratory franchise, and maintained a level of investment similar to 2010 in absolute terms. As a percentage over sales, R&D investment in 2011 reached almost 20%.

Corporate development agreements Almirall’s strategic priority is to continue its internationalisation process, increasing its critical mass where it already has affiliates, capitalising on its new products in new areas and being supported by partners when necessary.

Highlights of recent corporate development activities include the licensing of Almirall research compounds such as the antihistamine Ebastine in China and Southeast Asia; Aclidinium for chronic obstructive pulmonary disease (COPD) in Korea, Japan and more recently Europe. New products have also recently been incorporated in Spain (the oral anti-inflammatory roflumilast and the anticoagulant Rivaroxaban) and Italy (the antidepressant Escitalopram). Pipeline and growth platform evolution Almirall is focused on innovation to drive its growth and internationalisation strategy. It now has the most promising pipeline (R&D projects) in its history and significant progress was made in 2011 in its two main projects: Aclidinium for COPD and Linaclotide for irritable bowel syndrome with constipation (IBS-C).

The Aclidinium monotherapy administered through the Almirall inhaler Genuair^®, an easy to use and innovative device, was filed for registration in the USA and EU to treat moderate to severe COPD. This disease affects 210 million people worldwide and it is estimated to become the third leading cause of death by 2020. Almirall expects a regulatory response during 2012.

Linaclotide is a unique opportunity for IBS-C and responds to a significant unmet need for millions of patients, mostly women. It was filed for registration in Europe in 2011 and a regulatory response is expected during 2012.

About Almirall Almirall is an international pharmaceutical company based on innovation and committed to health. Headquartered in Barcelona, it researches, develops, manufactures and commercialises its own R&D and licensed drugs with the aim of improving people’s health and wellbeing. Almirall focuses its research resources on respiratory, gastrointestinal, dermatology and pain. Almirall’s products are currently present in over 70 countries in the five continents. It has direct presence in Europe and Latin America through 12 affiliates.

For further information please visit the website at: www.almirall.com

*Rounded -up figure

More information: Ketchum Pleon Sonia San Segundo sonia.sansegundo@ketchum.com Tel.: 00 34 91 788 32 00